来那度胺、硼替佐米与地塞米松治疗硬化性黏液水肿：1例病例报告及文献综述
Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature.
作者信息
Win Hninyee, Gowin Krisstina
机构信息
Department of Medicine University of Arizona Tucson Arizona.
Department of Hematology and Oncology University of Arizona Tucson Arizona.
出版信息
Clin Case Rep. 2020 Sep 17;8(12):3043-3049. doi: 10.1002/ccr3.3302. eCollection 2020 Dec.
Abstract
Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.
摘要
硬化性黏液水肿是一种罕见的进行性疾病，目前尚无标准治疗方法。来那度胺、硼替佐米和地塞米松三联疗法可能是治疗硬化性黏液水肿的有效疗法，尤其是对于难治性或复发性疾病患者。
相似文献
1
Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature.来那度胺、硼替佐米与地塞米松治疗硬化性黏液水肿：1例病例报告及文献综述
Clin Case Rep. 2020 Sep 17;8(12):3043-3049. doi: 10.1002/ccr3.3302. eCollection 2020 Dec.
2
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
3
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.浆细胞靶向治疗在单克隆丙种球蛋白病相关硬皮黏液水肿中的应用。
Blood. 2020 Apr 2;135(14):1101-1110. doi: 10.1182/blood.2019002300.
4
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.来那度胺、硼替佐米和地塞米松治疗复发和复发/难治性骨髓瘤患者的 2 期临床试验。
Blood. 2014 Mar 6;123(10):1461-9. doi: 10.1182/blood-2013-07-517276. Epub 2014 Jan 15.
5
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.来那度胺联合硼替佐米用于复发及复发/难治性多发性骨髓瘤的多中心、I期、剂量递增试验
J Clin Oncol. 2009 Dec 1;27(34):5713-9. doi: 10.1200/JCO.2009.22.2679. Epub 2009 Sep 28.
6
The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights.硼替佐米联合地塞米松治疗复发性/难治性硬肿性黏液水肿有效：一种具有新临床认识的罕见疾病。
Eur J Haematol. 2012 May;88(5):450-4. doi: 10.1111/j.1600-0609.2012.01772.x.
7
Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema.针对浆细胞的疗法可使重度或复发/难治性硬化性黏液水肿患者产生显著的临床反应且疗效持久。
J Eur Acad Dermatol Venereol. 2025 May;39(5):1011-1016. doi: 10.1111/jdv.20257. Epub 2024 Jul 31.
8
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.单克隆抗体与组蛋白去乙酰化酶抑制剂联合硼替佐米或来那度胺加地塞米松治疗复发或难治性多发性骨髓瘤：随机对照试验的间接比较荟萃分析。
J Immunol Res. 2018 Jun 27;2018:7646913. doi: 10.1155/2018/7646913. eCollection 2018.
9
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.来那度胺联合地塞米松方案治疗硼替佐米和来那度胺治疗后复发/难治性多发性骨髓瘤患者的疗效分析：KMM-166 研究。
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e97-e104. doi: 10.1016/j.clml.2019.10.017. Epub 2019 Oct 31.
10
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.来那度胺联合地塞米松添加达雷妥尤单抗或硼替佐米治疗新诊断多发性骨髓瘤的成本效果分析。
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
引用本文的文献
1
Skin-Colored Papules on the Face and Chest of a Female Patient.一名女性患者面部和胸部出现肤色丘疹。
Clin Case Rep. 2025 Sep 1;13(9):e70830. doi: 10.1002/ccr3.70830. eCollection 2025 Sep.
2
Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome.病例报告：硼替佐米对施尼茨勒综合征患者的治疗应用
Front Immunol. 2025 Jan 28;16:1520470. doi: 10.3389/fimmu.2025.1520470. eCollection 2025.
3
Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema.针对浆细胞的疗法可使重度或复发/难治性硬化性黏液水肿患者产生显著的临床反应且疗效持久。
J Eur Acad Dermatol Venereol. 2025 May;39(5):1011-1016. doi: 10.1111/jdv.20257. Epub 2024 Jul 31.
4
Dermato-neuro Syndrome after COVID-19 Vaccination in a Patient with Scleromyxoedema Previously Controlled with Bortezomib and Intravenous Immunoglobulins.1例曾用硼替佐米和静脉注射免疫球蛋白控制的硬化性黏液水肿患者接种新冠疫苗后出现皮肤神经综合征
Acta Derm Venereol. 2022 Dec 13;102:adv00836. doi: 10.2340/actadv.v102.4430.
5
Cutaneous manifestations of monoclonal gammopathy.单克隆丙种球蛋白病的皮肤表现。
Blood Cancer J. 2022 Apr 11;12(4):58. doi: 10.1038/s41408-022-00661-1.
本文引用的文献
1
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.浆细胞靶向治疗在单克隆丙种球蛋白病相关硬皮黏液水肿中的应用。
Blood. 2020 Apr 2;135(14):1101-1110. doi: 10.1182/blood.2019002300.
2
Increased frequency of interleukin-4 and reduced frequency of interferon-γ and IL-17-producing CD4+ and CD8+ cells in scleromyxedema.硬皮黏液水肿中白细胞介素-4频率增加，而产生干扰素-γ和白细胞介素-17的CD4+和CD8+细胞频率降低。
J Eur Acad Dermatol Venereol. 2020 May;34(5):1092-1097. doi: 10.1111/jdv.16136. Epub 2020 Jan 7.
3
High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease.大剂量静脉注射免疫球蛋白治疗皮肤自身免疫性疾病。
Front Immunol. 2019 Jun 11;10:1090. doi: 10.3389/fimmu.2019.01090. eCollection 2019.
4
High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system.大剂量静脉注射免疫球蛋白治疗硬肿性黏液水肿：采用客观临床评估系统评分的前瞻性开放性临床试验。
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1157-1160. doi: 10.1111/jdv.14244. Epub 2017 Apr 12.
5
Scleromyxedema.硬化性黏液水肿
Curr Opin Rheumatol. 2014 Nov;26(6):658-62. doi: 10.1097/BOR.0000000000000118.
6
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.静脉注射免疫球蛋白与来那度胺联合治疗硬肿病。
J Am Acad Dermatol. 2013 Aug;69(2):319-20. doi: 10.1016/j.jaad.2013.01.028.
7
Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.硬肿性黏液水肿：30 例患者的特征、合并症、病程和治疗的多中心研究。
J Am Acad Dermatol. 2013 Jul;69(1):66-72. doi: 10.1016/j.jaad.2013.01.007. Epub 2013 Feb 26.
8
Successful treatment of scleromyxedema with oral thalidomide.口服沙利度胺成功治疗硬肿病样黏液水肿。
Int J Dermatol. 2013 May;52(5):631-2. doi: 10.1111/j.1365-4632.2011.05030.x. Epub 2012 Dec 11.
9
Autoimmune/inflammatory syndrome (ASIA) induced by biomaterials injection other than silicone medical grade.由医用级硅酮以外的生物材料注射引起的自身免疫/炎症综合征（ASIA）。
Lupus. 2012 Oct;21(12):1326-34. doi: 10.1177/0961203312458838. Epub 2012 Sep 5.
10
Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature.硬化性黏液水肿与皮肤神经综合征：病例报告及文献综述
J Cutan Pathol. 2012 May;39(5):508-17. doi: 10.1111/j.1600-0560.2012.01882.x.
Zotero 插件